Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1644

Sort by

Sort Order Select

Journal Articles

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Blood (2025) 145 (23): 2685–2700.

https://doi.org/10.1182/blood.2024027270

Published: 2025

Includes: Supplemental data

Journal Articles

Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?

Mark Dalgetty, Jorge Cortes

Blood (2025) 145 (23): 2701–2708.

https://doi.org/10.1182/blood.2024027944

Published: 2025

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A , NUP98 , and GLIS2 rearrangements

Grace Egan, Sarah K. Tasian

Blood (2025) 145 (22): 2574–2586.

https://doi.org/10.1182/blood.2024026598

Published: 2025

Journal Articles

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood (2025) 145 (22): 2645–2655.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

Yanna Ding, Kikkeri N. Naresh

Blood (2025) 145 (22): 2672.

https://doi.org/10.1182/blood.2025028556

Published: 2025

Journal Articles

RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation

Madeline Y Mayday, Giulia Biancon, Manyi Wei, Christian Ramirez, Irene Moratti, Andreas P Pintado-Urbanc, Jether Amos Espinosa, Mi Chen, Lin Wang, Matthew D Simon, Yaara Ofir-Rosenfeld, Oliver Rausch, Toma Tebaldi, Stephanie Halene, Diane S Krause

Blood blood.2024027712.

https://doi.org/10.1182/blood.2024027712

Published: 2025

Includes: Supplemental data

Journal Articles

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia

Blood (2025) 145 (21): 2488–2506.

https://doi.org/10.1182/blood.2024028239

Published: 2025

Includes: Supplemental data

Journal Articles

Lymphoid malignancies in patients with Shwachman-Diamond syndrome

Helen D. Reed, Hyunwoo Do, Edie Weller, Marian H. Harris, Christopher R. Reilly, Harrison K. Tsai, Jason E. Farrar, Bonnie W. Lau, Lauren Pommert, Christopher Gamper, Ian Atkinson, Katherine Coyne, Margret Joos, Sara Loveless, Sarah Steltz, Leah Cheng, Maggie Malsch, Kasiani Myers, Akiko Shimamura

Blood (2025) 145 (21): 2528–2532.

https://doi.org/10.1182/blood.2024026507

Published: 2025

Journal Articles

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms

Blood blood.2024026940.

https://doi.org/10.1182/blood.2024026940

Published: 2025

Includes: Supplemental data

Journal Articles

FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells

Blood (2025) 145 (20): 2361–2373.

https://doi.org/10.1182/blood.2024025886

Published: 2025

Includes: Supplemental data

Journal Articles

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

Eman Khatib-Massalha, Christian Andrea Di Buduo, Agathe L Chédeville, Ya-Hsuan Ho, Yexuan Zhu, Elodie Grockowiak, Yuki Date, Lam Tan Khuat, Zijian Fang, Jose Quesada-Salas, Eva Carrillo Félez, Matteo Migliavacca, Isabel Montero, José Antonio Pérez-Simón, Alessandra Balduini, Simón Méndez-Ferrer

Blood blood.2024027455.

https://doi.org/10.1182/blood.2024027455

Published: 2025

Includes: Supplemental data

Journal Articles

How I Evaluate and Treat Resistance and Relapse in CML

Simona Soverini, Fausto Castagnetti

Blood blood.2024026511.

https://doi.org/10.1182/blood.2024026511

Published: 2025

Journal Articles

How I treat AML relapse after allogeneic HSCT

Mahasweta Gooptu, H. Moses Murdock, Robert J. Soiffer

Blood (2025) 145 (19): 2128–2137.

https://doi.org/10.1182/blood.2024025705

Published: 2025

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Blood (2025) 145 (19): 2138–2148.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Journal Articles

GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia

Blood (2025) 145 (19): 2179–2195.

https://doi.org/10.1182/blood.2024025761

Published: 2025

Includes: Supplemental data

Journal Articles

The JAK2 46/1 haplotype influences PD-L1 expression

Gonzalo Carreño-Tarragona, María Tiana, Raquel Rouco, Alejandra Leivas, Jesús Victorino, Roberto García-Vicente, Andrew J. Chase, Andrea Maidana, William J. Tapper, Rosa Ayala, Nicholas C. P. Cross, Joaquín Martínez-López, Miguel Manzanares

Blood (2025) 145 (19): 2196–2201.

https://doi.org/10.1182/blood.2023023787

Published: 2025

Includes: Supplemental data

Journal Articles

STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia

Andreas Linder, Daniel Nixdorf, Niklas Kuhl, Ignazio Piseddu, TengTeng Xu, Anne V. Holtermann, Gunnar Kuut, Rebekka Endres, Nora Philipp, Veit Bücklein, Johann de Graaff, Thomas Carell, Sebastian Kobold, Roman Kischel, Veit Hornung, Marion Subklewe

Blood (2025) 145 (19): 2149–2160.

https://doi.org/10.1182/blood.2024026934

Published: 2025

Includes: Supplemental data

Journal Articles

Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy

Rong He, Dong Chen

Blood (2025) 145 (19): 2230.

https://doi.org/10.1182/blood.2024028288

Published: 2025

Journal Articles

Delineating Mpl-dependent and -independent phenotypes of Jak2 V617F- positive MPNs in vivo

Nicolas Papadopoulos, Audrey Nédélec, Yacine Rahmani, Hosuk Ryou, Jean-Philippe Defour, Jens Rittscher, Daniel Royston, Stefan N. Constantinescu

Blood blood.2024026711.

https://doi.org/10.1182/blood.2024026711

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A , NUP98 , and GLIS2 rearrangements

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia

Lymphoid malignancies in patients with Shwachman-Diamond syndrome

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms

FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

How I Evaluate and Treat Resistance and Relapse in CML

How I treat AML relapse after allogeneic HSCT

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia

The JAK2 46/1 haplotype influences PD-L1 expression

STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia

Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy

Delineating Mpl-dependent and -independent phenotypes of Jak2 V617F- positive MPNs in vivo

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only